Nishida Haruyuki, Fujimori Ikuo, Arikawa Yasuyoshi, Hirase Keizo, Ono Koji, Nakai Kazuo, Inatomi Nobuhiro, Hori Yasunobu, Matsukawa Jun, Fujioka Yasushi, Imanishi Akio, Fukui Hideo, Itoh Fumio
Pharmaceutical Research Division: Takeda Pharmaceutical Company, Ltd., 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Pharmaceutical Research Division: Takeda Pharmaceutical Company, Ltd., 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Bioorg Med Chem. 2017 Jul 1;25(13):3447-3460. doi: 10.1016/j.bmc.2017.04.034. Epub 2017 Apr 27.
With the aim to discover a novel excellent potassium-competitive acid blocker (P-CAB) that could perfectly overcome the limitations of proton pump inhibitors (PPIs), we tested various approaches based on pyrrole derivative 1 as a lead compound. As part of a comprehensive approach to identify a new effective drug, we tried to optimize the duration of action of the pyrrole derivative. Among the compounds synthesized, fluoropyrrole derivative 20j, which has a 2-F-3-Py group at position 5, fluorine atom at position 4, and a 4-Me-2-Py sulfonyl group at the first position of the pyrrole ring, showed potent gastric acid-suppressive action and moderate duration of action in animal models. On the basis of structural properties including a slightly larger ClogP value (1.95), larger logD value (0.48) at pH 7.4, and fairly similar pKa value (8.73) compared to those of the previously optimized compound 2a, compound 20j was assumed to undergo rapid transfer to the stomach and have a moderate retention time there after single administration. Therefore, compound 20j was selected as a new promising P-CAB with moderately long duration of action.
为了发现一种新型的、能完美克服质子泵抑制剂(PPI)局限性的优秀钾离子竞争性酸阻滞剂(P-CAB),我们基于吡咯衍生物1作为先导化合物测试了各种方法。作为鉴定一种新的有效药物的综合方法的一部分,我们试图优化吡咯衍生物的作用持续时间。在合成的化合物中,氟吡咯衍生物20j在第5位具有2-F-3-Py基团,第4位有氟原子,并且在吡咯环的第一位有4-Me-2-Py磺酰基,在动物模型中显示出强效的胃酸抑制作用和适度的作用持续时间。基于包括略大的ClogP值(1.95)、在pH 7.4时较大的logD值(0.48)以及与先前优化的化合物2a相比相当相似的pKa值(8.73)等结构特性,推测化合物20j单次给药后会快速转移至胃部并在那里有适度的滞留时间。因此,化合物20j被选为一种有前景的、作用持续时间适中的新型P-CAB。